Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person15
One World Products, Inc.
Company
Dorman Products, Inc.
Company
Mueller Water Products, Inc.
Company
UTAH MEDICAL PRODUCTS INC
Company
NATURES SUNSHINE PRODUCTS INC
Company
GHST World Inc.
Company
Air Products & Chemicals, Inc.
Company
Outdoor Specialty Products, Inc.
Company
STANDARD MOTOR PRODUCTS, INC.
Company
UNIVERSAL SAFETY PRODUCTS, INC.
Company
Installed Building Products, Inc.
Company
Reynolds Consumer Products Inc.
Company
Feel The World, Inc.
Company
WOLVERINE WORLD WIDE INC /DE/
Company
Mission Produce, Inc.
Company
Primary record8
Evommune, Inc. filed 8-K
Item 1.01 Entry into a Material Definitive Agreement. Hinova Pharmaceuticals Inc. License Transaction License Agreement On November 4, 2026, Evommune, Inc. (the “Company”) entered into an Exclusive License Agreement (the
XCEL ENERGY INC filed 8-K
Item 8.01. Other Events. On October 30, 2026, Xcel Energy Inc. (“Xcel Energy”) entered into an equity distribution agreement (the “Equity Distribution Agreement”) with (i) Barclays Capital Inc., BMO Capital Markets Corp.
One World Products, Inc. filed 8-K
Item 7.01. Regulation FD Disclosure. On October 27, 2026, One World Products, Inc. (the “Company”) issued a press release announcing that it has entered into a strategic investment and commercial partnership agreement wi
Zymeworks Inc. filed 8-K
ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT On October 22, 2026, Zymeworks Inc. and its subsidiary Zymeworks BC Inc. (together, the “Company”) entered into a Collaboration and License Agreement (the “Collaborati
Paramount Skydance Corp filed 8-K
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 27, 2026, the Board of Directors (the Board ) of P
Intellia Therapeutics, Inc. filed 8-K
Item 7.01 Regulation FD Disclosure. On September 8, 2026, Intellia Therapeutics, Inc. (the “Company” or “Intellia”) issued a press release titled “Intellia Therapeutics Announces FDA Acceptance of Biologics License Appli
Zoom Communications, Inc. filed 8-K
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Appointment of Jeff Epstein On and effective as of August 31, 20
Lord Abbett Private Credit Fund S filed 8-K
Item 3.02. Unregistered Sales of Equity Securities. As of August 1, 2026, Lord Abbett Private Credit Fund S ( we , the Company or the Fund ), issued and sold approximately 209,520 of the Company s common shares of benefi